iLABMED最新文献

{"title":"Candidate reference measurement procedure for serum 17-hydroxyprogesterone quantification via isotope dilution liquid chromatography–tandem mass spectrometry","authors":"Ji Zhang,&nbsp;Yang Jiang,&nbsp;Ting Liu,&nbsp;Xiongwei Liu,&nbsp;Hui Huang,&nbsp;Yanxiang Cheng,&nbsp;Jieyan Li,&nbsp;Bangning Cheng,&nbsp;Chungen Qian,&nbsp;Xufu Xiang,&nbsp;Jun-Fa Xu","doi":"10.1002/ila2.39","DOIUrl":"10.1002/ila2.39","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Accurate quantification of 17-hydroxyprogesterone (17-OHP) in serum is vital for clinical and research applications. However, inter-laboratory variability in test results exists owing to the lack of a standardized reference measurement procedure (RMP). Therefore, in this study, we developed a highly accurate, cost-effective, and user-friendly candidate RMP (cRMP) for analyzing 17-OHP in serum.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We quantified 17-OHP in serum using a one-step liquid–liquid extraction method with the addition of 17-OHP-¹³C₃, followed by liquid chromatography–tandem mass spectrometry. The ability of these methods to suppress interference was evaluated by chromatographic analysis. We assessed accuracy, specificity, the lower limit of quantitation, linearity, and matrix effects by following the standards specified by the Clinical and Laboratory Standards Institute. The consistency between the developed cRMP and the chemiluminescence method was evaluated through experiments with 120 clinical samples.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The developed cRMP required only 8 min for accurate quantification of serum 17-OHP without bias from matrix effects or interference from 19 metabolites added as potential interferents. The method exhibited favorable measurement performance, with a quantitation limit of 0.086 ng/mL, linear range of 0.1–400 ng/mL, a total imprecision of ≤2.90%, spike recovery of 100.1%–100.6%, and relative deviations from assigned target values (RfB Institution) of −2.91% to 1.10%. The cRMP demonstrated good consistency with the conventional assay (chemiluminescence method), with a correlation coefficient <i>R</i> of 0.96977.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A cRMP with high accuracy, cost-effectiveness, and convenient operation was developed for quantifying 17-OHP in serum. Its simplicity and robust performance make it an invaluable addition to the arsenal of analytical tools available for laboratories. This method can enhance the accuracy and reliability of 17-OHP measurements across various laboratories.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 2","pages":"98-107"},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.39","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140655961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant and sequential administration of nirmatrelvir-ritonavir and azvudine in patients with COVID-19 caused by the Omicron variant: Safety and efficacy","authors":"Guang-Bin Chen,&nbsp;You-Rou Zheng,&nbsp;Yun-Ni Yu,&nbsp;Li-Mian Liang,&nbsp;Chao Chen,&nbsp;Ying-Xia Liu,&nbsp;Hong-Zhou Lu","doi":"10.1002/ila2.40","DOIUrl":"10.1002/ila2.40","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study assessed the safety and efficacy of nirmatrelvir-ritonavir (Paxlovid®) and azvudine when administered sequentially or concomitantly in patients with coronavirus 2019 (COVID-19) caused by the Omicron variant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Ninety-three patients confirmed to be infected with the Omicron variant by nucleic acid detection were retrospectively investigated. Information was collected on general health status, medication, and adverse drug reactions (ADRs) according to whether nirmatrelvir-ritonavir and azvudine were administered sequentially or concomitantly. Data on times of onset, clinical manifestations, and outcomes of ADRs and on conversion to a negative nucleic acid test were also recorded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Possible ADRs were recorded in 41 patients (44.1%). There were 22 gastrointestinal reactions in 18 patients and 18 hematological abnormalities in 16 after sequential or concomitant treatment with nirmatrelvir-ritonavir and azvudine. Liver enzyme levels increased in nine cases and creatinine clearance decreased in two. Cases of atrial fibrillation (<i>n</i> = 1), sleep disorder (<i>n</i> = 2), rash (<i>n</i> = 2), dizziness (<i>n</i> = 1), and weakness (<i>n</i> = 5) were also documented. Only vomiting, poor appetite, diarrhea, xerostomia, bitter taste, and rash were considered probable ADRs; others were thought to be possible ADRs. In all cases, the nucleic acid test did not turn negative after the first antiviral was applied. The nucleic acid test of 28 patients did not turn negative before discharge. The remaining 65 patients (69.9%) returned a negative nucleic acid test after receiving the second antiviral agent.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Treatment with nirmatrelvir-ritonavir and azvudine is safe and effective whether administered sequentially or concomitantly in patients with COVID-19 caused by the Omicron variant.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 2","pages":"88-97"},"PeriodicalIF":0.0,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.40","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140675770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and risk factors for mortality in Candida auris infections","authors":"Kang Li,&nbsp;Xin Liu,&nbsp;Danfeng Liu,&nbsp;Yuqi Zhi,&nbsp;Chang Dong,&nbsp;Pengrui Sun,&nbsp;Yueming Dong,&nbsp;Hongfang Pan,&nbsp;Yuxiang Zhang,&nbsp;Hong Lei","doi":"10.1002/ila2.38","DOIUrl":"https://doi.org/10.1002/ila2.38","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p><i>Candida auris</i> infections pose a threat to public health, necessitating increased awareness in China. This study aimed to analyze the strains of <i>C</i>. <i>auris</i>, assess the infection status, and investigate clinical characteristics and risk factors for mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective analysis was conducted on 18 patients with <i>Candida auris</i> infection. We focused on evaluating basic characteristics, strain sources, and antibacterial susceptibility test results. Statistical methods were used to determine clinical features and identify risk factors for death.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The strain type, composition ratio, and specimen source of <i>C</i>. <i>auris</i> were not associated with mortality. Neither the infection index nor the length of hospitalization showed an association with the prognosis. However, significant risk factors for mortality included cerebral infarction, cardiac disease, renal dysfunction, hypoproteinemia, and anemia (all <i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Cerebral infarction, cardiac disease, renal dysfunction, hypoproteinemia, and anemia are significant risk factors for death in <i>C</i>. <i>auris</i> infections. These findings indicate the importance of recognizing and addressing these factors in the clinical management of <i>C</i>. <i>auris infection</i>.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 2","pages":"79-87"},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.38","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141435644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in the system accuracy acceptability of four types of blood glucose monitoring systems against five different standards","authors":"Tengjiao Wang,&nbsp;Lina Zhang,&nbsp;Lijun Gong,&nbsp;Yangmei Xin,&nbsp;Liang Han,&nbsp;Na Li,&nbsp;Peng Peng,&nbsp;Xiuying Zhao,&nbsp;Runqing Li","doi":"10.1002/ila2.37","DOIUrl":"10.1002/ila2.37","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to evaluate the system accuracy of four types of blood glucose monitoring systems (BGMSs) and explore the differences in the system accuracy acceptability of each BGMS against five different standards.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The glucose measurement values obtained from four types of BGMSs (Roche Accu-Chek^® Performa, Bayer Contour™ TS, Sinomedisite Glupad^® H1 Plus, and Sinocare^® Gold-Accu) were evaluated against the reference values obtained from the biochemical analyzer of the central laboratory. The system accuracy acceptability of each BGMS was determined using the criteria specified in five standards, namely the International Organization for Standardization (ISO) 15197:2003, Clinical Laboratory Standards Institute (CLSI) POCT12-A3, ISO 15197:2013, Chinese Society of Laboratory Medicine (CSLM) consensus, and US Food and Drug Administration (FDA) guidelines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From 2018 to 2022, 10,980 pairs of measurement values were obtained from 366 glucose meters of four types of BGMSs. Significant correlations were observed between the glucose measurement values from the BGMSs and the reference values from the biochemical analyzer of the central laboratory. The correlation coefficient <i>r</i> was 0.995 for Roche Accu-Chek^® Performa, 0.994 for Bayer Contour™ TS, 0.983 for Sinomedisite Glupad^® H1 Plus, and 0.997 for Sinocare^® Gold-Accu. The acceptability criteria specified in ISO 15197:2003 were met by 100.00% (135/135) of the glucose meters of Roche Accu-Chek^® Performa, 100.00% (109/109) of Bayer Contour™ TS, 81.61% (71/87) of Sinomedisite Glupad^® H1 Plus, and 100.00% (35/35) of Sinocare^® Gold-Accu. Whereas, the acceptability criteria specified in ISO 15197:2013 were met by 99.26% (134/135) of the glucose meters of Roche Accu-Chek^® Performa, 88.07% (96/109) of Bayer Contour™ TS, 58.62% (51/87) of Sinomedisite Glupad^® H1 Plus, and 91.43% (32/35) of Sinocare^® Gold-Accu.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Among the four types of BGMSs evaluated, the glucose meters of Roche Accu-Chek^® Performa exhibited superior system accuracy. The system accuracy acceptability of each BGMS varied significantly against the acceptability criteria specified in the five different standards.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 2","pages":"70-78"},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.37","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140224341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A preliminary study of the mechanism of compound hearing loss caused by ototoxic drugs combined with impulse noise","authors":"Xin Qiu,&nbsp;Qing-qing Jiang,&nbsp;Wei-wei Guo,&nbsp;Ning Yu,&nbsp;Shi-ming Yang","doi":"10.1002/ila2.34","DOIUrl":"10.1002/ila2.34","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hearing loss (HL) is becoming increasingly common and is more commonly caused by noise, ototoxic substances, or a combination of ototoxic factors. However, so far, few studies have examined the mechanism by which compound factors cause HL. The only relevant study is about occupational ototoxic substances combined with environmental noise at 85–110 dB SPL. In this study, to address the shortcomings of existing research, we innovatively focused on HL induced by loud noise (impulse noise, &gt;160 dB SPL) combined with common ototoxic drugs. The aim of this study was to establish and validate a mature animal model, and then to compare the characteristics of audiology, pathomorphology and molecular features, and to preliminarily predict pathogenesis in compound HL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We selected guinea pigs to construct in vivo HL model groups for different extents of exposure, including a blank control group, a single-drug group, a single-impulse noise group, and a compound group. The animal model of the mature compound HL group was established using gentamicin combined with impulse noise. We then performed audiological and pathological verification. We analyzed the auditory brainstem response (ABR), pathological morphology of the cochlea, and molecules (including important self-radicals, cytokines, and apoptosis signal transduction pathway proteins in the pathogenesis of drug- and noise-induced HL), compared the effect of different extents of exposure on HL, and preliminarily predict the pathogenic mechanism of compound HL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Four groups of animal models were established successfully and verified by audiology and pathology. Regarding audiology, there were no significant differences in the ABR thresholds before exposure (<i>p</i> &gt; 0.05), but differences emerged among the groups after exposure. Notably, after 3, 7, and 14 days of exposure, there were significant differences in the ABR thresholds between the compound group and both the drug and noise groups (<i>p</i> &lt; 0.01), and after 14 days, the HL of the compound group was much more severe (greater than the linear sum of single-factor HL group). Regarding the pathomorphology, compared with the control group, the cochleae were damaged to different degrees in the factor exposure groups. The drug group had the least severe HL, the noise group had serious HL (<i>p</i> &lt; 0.05), and the compound group had the most severe HL (<i>p</i> &lt; 0.01). The compound group's damage was greater than the linear sum of the single-factor group in many ways, such as the loss and damage o","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 1","pages":"38-52"},"PeriodicalIF":0.0,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.34","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140245830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of severe monkeypox case with advanced HIV infection using plasma from smallpox-vaccinated healthy population: A case report","authors":"Chuming Chen,&nbsp;Weiming Yao,&nbsp;Siran Huang,&nbsp;Ling Peng,&nbsp;Shiyan Feng,&nbsp;Weibo Wu,&nbsp;Yunlan Yi,&nbsp;Zhiqiang Cheng,&nbsp;Yang Yang,&nbsp;Yan Yang,&nbsp;Liuqing Yang,&nbsp;Hongzhou Lu,&nbsp;Fuxiang Wang","doi":"10.1002/ila2.32","DOIUrl":"10.1002/ila2.32","url":null,"abstract":"<p>Since the first reported case of monkeypox in the UK in May 2022, there has been an upward trend in monkeypox cases and a global outbreak. However, reports of severe cases are relatively limited. In this study, we report a case of severe monkeypox in a patient with HIV. The patient presented with skin lesions that started on his face and around the penis and persisted for several months. Throughout the course of the disease, he received systematic symptomatic supportive treatment, topical remedies, and special care for the rash. He also underwent cidofovir antiviral therapy and smallpox-vaccinated healthy population-derived plasma therapy in succession, with the condition ultimately showing improvement after plasma treatment. After more than 3 months of hospitalization, he fully recovered. To the best of our knowledge, this is the first reported use of smallpox-vaccinated healthy population-derived plasma in the treatment of severe monkeypox cases.</p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 1","pages":"60-66"},"PeriodicalIF":0.0,"publicationDate":"2024-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.32","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140255168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic approaches for monkeypox virus","authors":"Guohao Fan,&nbsp;Jiahua Kuang,&nbsp;Shengjie Zhang,&nbsp;Yang Yang,&nbsp;Yingxia Liu,&nbsp;Hongzhou Lu","doi":"10.1002/ila2.36","DOIUrl":"10.1002/ila2.36","url":null,"abstract":"<p>Mpox (formerly Monkeypox) is a zoonotic infection caused by Monkeypox virus (MPXV). Since 2022, Mpox epidemics have occurred in many non-endemic countries and regions, leading the World Health Organization to declare a public health emergency of international concern. With the persistent transmission and evolution of MPXV, symptoms of Mpox have become milder, with some infections being asymptomatic. In addition, MPXV has become more contagious. Therefore, rapid and accurate diagnosis and screening of MPXV is vital to prevent and control MPXV epidemics. Here, we review and summarize the technical details, application scenarios, and the advantages and disadvantages of MPXV-specific diagnostic methods.</p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 1","pages":"6-13"},"PeriodicalIF":0.0,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.36","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140259101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From bench to bedside: Opportunities and challenges for iLABMED","authors":"Tetsuya Asakawa,&nbsp;Yi-Wei Tang,&nbsp;Hongzhou Lu","doi":"10.1002/ila2.33","DOIUrl":"https://doi.org/10.1002/ila2.33","url":null,"abstract":"<p>Since the new <i>iLABMED</i> was founded in June 2023, it has published three issues with 21 articles (till Dec 2023). As a journal majored in laboratory medicine, <i>iLABMED</i> also has to face many opportunities and challenges of laboratory medicine. This editorial summarized the main opportunities and challenges faced by <i>iLABMED</i>. The future prospects of laboratory medicine, which must be highlighted by <i>iLABMED</i> were also discussed based on a brief review of the current advances in laboratory medicine. <i>iLABMED</i> will continue to provide a useful platform for general-interested, insightful, and informative articles with high quality.</p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.33","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140291380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pseudomonas aeruginosa infections and improper storage conditions influence the performance of 1,3-β-d-glucan in diagnosis of invasive fungal infections","authors":"Zilan Wei,&nbsp;Jie Xu,&nbsp;Fang Yuan,&nbsp;Wendong Fang,&nbsp;Jiahui Wu,&nbsp;Youliang Wang,&nbsp;Shuiping Chen","doi":"10.1002/ila2.35","DOIUrl":"https://doi.org/10.1002/ila2.35","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The association between 1,3-<i>β</i>-<span>d</span>-glucan (BDG) levels and infections caused by <i>Pseudomonas aeruginosa</i> or <i>Streptococcus pneumoniae</i>, and the stability of BDG under different storage conditions are unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Strains of <i>Pseudomonas aeruginosa</i> and <i>S</i>. <i>pneumoniae</i> were grown in medium and human serum. The BDG concentrations in culture supernatants were measured. The specificity and stability of BDG were also evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p><i>P</i>. <i>aeruginosa</i> produced high levels of BDG in Luria–Bertani medium (&gt;4 × 10⁴ pg/mL) and human serum (527.0 pg/mL), whereas <i>S</i>. <i>pneumoniae</i> produced low levels of BDG in THY medium (175.6 pg/mL) and human serum (78.3 pg/mL). The BDG produced by these two bacteria was specifically degraded by 1,3-<i>β</i>-<span>d</span>-glucanase. BDG was degraded when stored at different temperatures, decreasing by 22.5% and 9.3% at −20°C and −70°C, respectively, for 63 days; by 30.7% at 4°C for 12 days; and by 12.6% and 22.0% at 37°C for 6 and 12 h.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>BDG false-positivity must be considered in patients with bacteremia caused by <i>P</i>. <i>aeruginosa</i> when diagnosing invasive fungal infection. Human serum samples for the BDG test in medical facilities should be tested as soon as possible or stored at low temperatures before testing.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 1","pages":"53-59"},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.35","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140291358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers for predicting efficacy of chimeric antigen receptor T cell therapy and their detection methods","authors":"Bo Zou,&nbsp;Yanzhou Song,&nbsp;Ning Li,&nbsp;Zhongyi Fan,&nbsp;Jie Li,&nbsp;Yuanzheng Peng,&nbsp;Wanshan Wei,&nbsp;Yuzi Zhang,&nbsp;Yinan Su,&nbsp;Xianmin Meng,&nbsp;Hongzhou Lu,&nbsp;Xingding Zhang,&nbsp;Xiaohua Tan,&nbsp;Qibin Liao","doi":"10.1002/ila2.31","DOIUrl":"10.1002/ila2.31","url":null,"abstract":"<p>Cancer immunotherapy has emerged as the fourth most prevalent approach to tumor treatment, alongside surgery, radiotherapy, and chemotherapy. After several decades of development, chimeric antigen receptor T (CAR-T) cell therapy, a promising branch of adoptive T-cell therapy, has demonstrated superior efficacy and safety in comparison to other cell therapies in the treatment of cancer. At present, CAR-T cells are predominantly used to treat hematological malignancies, although their application in solid tumors is being readily investigated. Although numerous studies have examined the biomarkers associated with the safety of CAR-T cell therapy, few have evaluated predictors of CAR-T cell therapeutic efficacy. Thus, the primary objective of this review article was to provide a comprehensive overview of the factors predicting the efficacy of CAR-T cell therapy, with a particular focus on biomarkers and their detection methods.</p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 1","pages":"14-26"},"PeriodicalIF":0.0,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.31","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139960910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}